Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel J Bundred

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
NPJ Breast Cancer|May 29, 2021
FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activitySimon Timbrell, Hosam Aglan, Angela Cramer, et al.
Integrative Cancer Therapies|January 24, 2017
Recruitment to the "Breast-Activity and Healthy Eating After Diagnosis" (B-AHEAD) Randomized Controlled TrialMary Pegington, Judith E Adams, Nigel J Bundred, et al.
BMJ (Clinical Research Ed.)|September 21, 2022
Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysisJames R Bundred, Sarah Michael, Beth Stuart, et al.
Trials|August 29, 2020
Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trialJohn Castle, Emma Blower, Nigel J Bundred, et al.
The Lancet. Oncology|December 15, 2010
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trialJack Cuzick, Ivana Sestak, Sarah E Pinder, et al.
Cancer Medicine|January 22, 2020
Breast cancer stromal clotting activation (Tissue Factor and thrombin): A pre-invasive phenomena that is prognostic in invasionHudhaifah Shaker, Nigel J Bundred, Göran Landberg, et al.
Cancer|January 22, 2008
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study resultsNigel J Bundred, Ian D Campbell, Neville Davidson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trialNigel J Bundred, Angela Cramer, Julie Morris, et al.
The Lancet. Oncology|January 27, 2009
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trialPeter Kenemans, Nigel J Bundred, Jean-Michel Foidart, et al.
Breast Cancer Research : BCR|January 19, 2012
Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudyNigel J Bundred, Peter Kenemans, Cheng Har Yip, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
NPJ Breast Cancer|May 29, 2021
FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activitySimon Timbrell, Hosam Aglan, Angela Cramer, et al.
Integrative Cancer Therapies|January 24, 2017
Recruitment to the "Breast-Activity and Healthy Eating After Diagnosis" (B-AHEAD) Randomized Controlled TrialMary Pegington, Judith E Adams, Nigel J Bundred, et al.
BMJ (Clinical Research Ed.)|September 21, 2022
Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysisJames R Bundred, Sarah Michael, Beth Stuart, et al.
Trials|August 29, 2020
Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trialJohn Castle, Emma Blower, Nigel J Bundred, et al.
The Lancet. Oncology|December 15, 2010
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trialJack Cuzick, Ivana Sestak, Sarah E Pinder, et al.
Cancer Medicine|January 22, 2020
Breast cancer stromal clotting activation (Tissue Factor and thrombin): A pre-invasive phenomena that is prognostic in invasionHudhaifah Shaker, Nigel J Bundred, Göran Landberg, et al.
Cancer|January 22, 2008
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study resultsNigel J Bundred, Ian D Campbell, Neville Davidson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trialNigel J Bundred, Angela Cramer, Julie Morris, et al.
The Lancet. Oncology|January 27, 2009
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trialPeter Kenemans, Nigel J Bundred, Jean-Michel Foidart, et al.
Breast Cancer Research : BCR|January 19, 2012
Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudyNigel J Bundred, Peter Kenemans, Cheng Har Yip, et al.
Pageof 5